Clinical Trial: To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A 24 Week, Multi-centre, Open Label, Non Controlled Study to Assess the Efficacy of Valsartan in Reducing Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diab

Brief Summary: This study is designed to assess the efficacy of the different dosage forms of Valsartan[80, 160, and 320 mg] in reducing microalbuminuria/proteinuria in hypertensive patients with type 2 diabetes.

Detailed Summary:
Sponsor: Novartis

Current Primary Outcome: Change in Albumin Creatinine Ratio (ACR) from baseline over a period of 24 weeks. [ Time Frame: Week 24 ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Percent reduction of (BP) at 24 weeks compared to baseline level. Percent of patients whose BP is controlled at 24 weeks (< 130/80) [ Time Frame: Week 24 ]

Original Secondary Outcome: Same as current

Information By: Novartis

Dates:
Date Received: October 24, 2007
Date Started: June 2007
Date Completion:
Last Updated: February 21, 2017
Last Verified: February 2017